Lilly(US:LLY) GLP1减重宝典·2026-03-12 14:17Core Viewpoint - Eli Lilly issued a public warning regarding the presence of significant impurities formed from the chemical reaction between tirzepatide and vitamin B12 in compounded products in the U.S. market, raising concerns about patient safety and regulatory compliance [2][4]. Group 1: Warning and Impurities - The core of Eli Lilly's warning is not against vitamin B12 itself, but rather the new impurities generated when mixed with tirzepatide, which currently lack clear human data regarding their short-term or long-term effects [4]. - Eli Lilly emphasized that the risks associated with these impurities remain unclear, including their potential impact on the interaction between tirzepatide and GLP-1 or GIP receptors, as well as their absorption, distribution, metabolism, and excretion pathways in the body [4][6]. Group 2: Market Dynamics and Regulatory Concerns - The warning reflects a broader issue within the U.S. weight loss drug supply chain, where the demand for GLP-1 drugs has led to a rapid expansion of compounded products, often marketed as personalized versions but lacking regulatory oversight [6][7]. - Eli Lilly's findings indicate that the issue is not isolated, as testing revealed similar impurities across various products in the U.S. market, suggesting a systemic problem rather than a rare occurrence [6][7]. Group 3: Implications for the Compounded GLP-1 Market - The presence of impurities from mixing tirzepatide with other substances, such as glycine and niacinamide, signals a broader warning for the compounded GLP-1 market, indicating that the risks may extend beyond just vitamin B12 [7]. - Eli Lilly's public statement challenges the narrative of personalized medicine in this context, suggesting that many compounded products are not genuinely individualized but rather attempts to differentiate from original drugs under regulatory pressure [6][7].